Ripretinib Continues to Demonstrate Benefit in Advanced GIST
An updated analysis of the phase III INVICTUS trial showed improved survival in patients with advanced gastrointestinal stromal tumors (GIST) treated with ripretinib (Qinlock) as later-line therapy, a researcher reported. At 19 months after the primary analysis, median progression-free survival (PFS) with the fourth- or later-line therapy remained stable, at 6.3 months with ripretinib versus […]